Lupin Limited · NSE:LUPIN
Lupin — Q2 FY25 Earnings Presentation
22 slides from Lupin's earnings presentation, Nov 7, 2024
Slide 1: Exchange filing cover letter
November 07, 2024 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Investor Presentation - Q2 FY25. Dear Sir
Slide 2: Investor Presentation Q2 FY25
Investor Presentation Q2 FY25 Nov 7, 2024
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q2FY25 Performance
LUPIN Q2FY25 Perforn
Slide 5: Q2FY25: Key Growth Metrics
Q2FY25: Key Growth Metrics Strong execution on all fronts Key Metrics Business Performance INR mn India North America 54,970 mn 20,096 mn 19,711 mn Sales 19% YoY 6% YoY 11% YoY 13,083 mn 23.8% Growth Markets EMEA EBITDA1 Margin 4,896 mn 5,693 mn 12% YoY 20% YoY 42% YoY API ROW 8,526 mn 15.5% 2,944 m
Slide 6: Q2FY25: Key Developments
Q2FY25: Key Developments Consistent trajectory of improved profitability Financials Key Launches Sales* and EBITDA margin Trajectory Doxorubicin Generic of Mirabegron Generic of Doxil® 60,000 30.0% HCL Liposome 55,143 54,970 (50mg) Myrbetriq® 49,392 50,799 48,951 Inj. (Liposomal) 50,000 25.0% Busine
Slide 7: Q2FY25 Financial Snapshot
Q2FY25 Financial Snapshot Sales Mix Key Financials INR mn Revenue (In INR mn and %) India, Q2 FY25 Q2 FY24 Q1 FY25 20,096, 37% North America, Sales 54,970 49,392 55,143 19,711, 36% API, 2,944, 5% EBITDA1 13,083 9,232 12,864 ROW, Growth EMEA, Markets, 1,629, 5,693, 4,896, 9% Net Income2 8,526 4,897 8
Slide 8: India: Outperforming market growth
India: Outperforming market growth Leveraging chronic leadership with improved India business grew ~19% YoY in Q2FY25 productivity India Sales (INR mn) 16,915 17,251 16,015 19,259 20,096 #2 rank #3 rank #3 rank Respiratory Diabetes Care Cardiac • Chronic segment (~62% of sales) grew 13.5% YoY vs IPM
Slide 9: India: Amplifying our Core
India: Amplifying our Core Lupin prescription business is positioned to outperform Enabling end to end healthcare ecosystem and access IPM with key drivers in place for the patient Enhancing penetration and reach CHC Portfolio catering to GI, • Maximizing Chronic therapy focus Business Verticals VMS
Slide 10: North America: Delivering on Complex Generics
North America: Delivering on Complex Generics Leadership: 4.1% TRx Consistent trajectory in Growing Respiratory volume share in U.S.1 sales portfolio US Sales ($mn) 213 212 209 227 220 #3 #1 21.6% 27.4% in the US1 in 51 products2 Albuterol Arfomoterol Q2 Q3 Q4 Q1 Q2 market share market share Maintai
Slide 11: Other Markets: Key Highlights
Other Markets: Key Highlights Consistent growth in Key Markets • Strong double-digit growth • BRL ~62mn sales4 in Q2FY25 (flat witnessed in UK Brazil QoQ growth) EU • Growth driven by higher • Rank 2nd in reference market3 Luforbec® & NaMuscla® • 8th largest generics player1 • Revenues up 166% YoY4
Slide 12: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and Achieve Best-in-Class Quality biosimilars Substantial Capabilities to become CGx powerhouse Recent Track Record • Inhalation: Global presence with end-to-end capabilities Successful outcomes in last 6 months of MDIs, DPIs, Soft-Mist In
Slide 13: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend R&D (INR mn) Capex (INR mn) Net debt/ Equity 5,000 4,481 15.0% 2,000 1,848 15.0% 0.16 4,500 4,255 1,800 0.14 13.0% 13.0% 0.14 4,000 3,764 3,567 1,600 1,449 11.0% 3,500 11.0% 1,345 0.12 3,500 1,400 3,000 9.0% 1,200 1,059 1,117 9.0% 0.10 2,500 8.7% 8.2% 7.0% 1,00
Slide 14: P&L Highlights Q2 FY25
P&L Highlights Q2 FY25 YoY QoQ Amount in INR mn Q2’FY25 % of Sales Q2’FY24 % of Sales Q1’FY25 % of Sales Growth Growth Net Sales 54,970 100.00% 49,392 100.00% 11.3% 55,143 100.00% -0.3% Other operating income 1,757 3.2% 994 2.0% 76.8% 860 1.6% 104.3% Total revenue 56,727 103.2% 50,386 102.0% 12.6% 5
Slide 15: P&L Highlights H1 FY25
P&L Highlights H1 FY25 YoY Amount in INR mn H1’FY25 % of Sales H1’FY24 % of Sales Growth Net Sales 110,113 100.0% 96,813 100.0% 13.7% Other operating income 2,617 2.4% 1,714 1.8% 52.7% Total revenue 112,730 102.4% 98,527 101.8% 14.4% Gross Profit (excl. other operating 75,768 68.8% 63,378 65.5%* 19.
Slide 16: Lupin at a Glance
hd LUPIN Lupin at a ¢
Slide 17: Lupin Today
Lupin Today Operating from a position of strength Global Presence Local Leadership Geographically Diverse (FY24 Sales) 12th Largest in 7th India Pharma 9% Largest Generic 3 rd the US Market Rank 34% INDIA Developed Company (by prescriptions2) Markets (by sales4) (by sales1) 37% Largest Largest US $2
Slide 18: Vision
Vision A pharmaceutical company focused on delivering high quality medicines to patients around the world Global Other United Developed India Region Emerging API States Markets Markets Evolving portfolio and Global operational Delivering innovative pipeline in Complex Global reach and scale as effic
Slide 19: Lupin's ESG Update
Lupin’s ESG Update Progressing steadily in reaching our ambitious long-term ESG targets ESG Goal Status FY 2024 Key Highlights in H1FY25 Climate 38% GHG Reduction 21% GHG Change 1 by 2030 Reduction 21 MW of renewable solar open access successfully signed for Tarapur facility in Maharashtra. 50% recy
Slide 20: ESG: Ratings update in FY24
ESG: Ratings update in FY24 Committed to accountability and public disclosure of ESG initiatives. Our performance is reflected in year-on-year progress across ESG ratings Agency 2021 2022 2023 2024 ESG Score 17 46 69 76 Score yet to be Climate F C B released for 2024 - F C Score yet to be released f
Slide 21: Lupin – Awards and Accolades
Lupin – Awards and Accolades • ‘Breakthrough Launch of the Year’ Award (brand Valentas) at the National Feather Healthcare and Pharma Awards in association with the Economic Times • Humrahi, Lupin’s Patient Support Program for Diabetes Management, recognized as a ‘Patient-Centric Pharma Program in D
Slide 22: Thank You
Thank You Registered Address 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400055, India Phone: +91 22664 02323 | Fax: +91 22664 02051 lupin.com youtube.com/c/LupinGlobal x.com/LupinGlobal facebook.com/LupinWorld/ linkedIn.com/company/lupin